Special Issue

Neuroendocrine Tumors: Challenges and Future Perspectives (Second Edition)

Message from the Guest Editors

Neuroendocrine tumors (NETs) are a family of neoplasms of increasing incidence and prevalence worldwide. Their heterogeneity in terms of biological aggressiveness, variegated site of origin and capability to potentially produce hormonally active substances poses unique challenges for clinical management. NETs are characterized by the peculiar and frequent expression on the cell surfaces of somatostatin receptors, which represents the ideal target for therapy (i.e., somatostatin analogues (SSAs) and peptidereceptor radionuclide therapy (PRRT)), Few chemotherapy schemes are currently part of the therapeutic armamentarium. However, regardless of the huge number of clinical trials and many promising new drugs, the only approved targeted agents for advanced progressive NETs are everolimus and sunitinib (the second one only for those of pancreatic origin). Additionally, despite great efforts in the search for innovative biomarkers, only few validated biomarkers are available thus far. Following the success of the first volume of the Special Issue, a second volume is announced here with the aim to highlight recent advances in NFTs.

Guest Editors

Dr. Anna La Salvia

National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy

Dr. Giuseppe Lamberti

Department of Medical or Surgical Sciences (DIMEC), S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Deadline for manuscript submissions

20 February 2026



Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/204627

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 icm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).